Clinical Effects of a Commercial Supplement of Ophiocordyceps sinensis and Ganoderma lucidum on Cognitive Function of Healthy Young Volunteers

2017 ◽  
Vol 19 (8) ◽  
pp. 667-673 ◽  
Author(s):  
Sharon Tsuk ◽  
Jorden Har Lev ◽  
Arie Rotstein ◽  
Rafi Carasso ◽  
Aviva Zeev ◽  
...  
2021 ◽  
pp. 1357633X2110451
Author(s):  
Maryam Bemanalizadeh ◽  
Maryam Yazdi ◽  
Omid Yaghini ◽  
Roya Kelishadi

Introduction This study aims to report the effect sizes of telemedicine treatments on the symptom domains of paediatric ADHD. Methods In this systematic review and meta-analysis, electronic databases, i.e. PubMed, Scopus, Web of Science and Embase, were searched for articles published up to December 2020. The inclusion criteria were as follows: children or adolescents diagnosed for ADHD or other hyperkinetic disorders; randomized controlled trials (RCTs); efficacy established with parents and teachers or self-rating scales at least for one of the following domains: inattention, cognitive function, hyperactivity, hyperactivity/impulsivity or oppositional behaviours. The risk of bias was assessed using the Cochrane risk of bias tool for RCTs. Results From 310 records reduced to 228 after removing duplicates, overall 12 studies were fulfilled our inclusion criteria. They consisted of 708 participants (358 with telemedicine intervention and 350 controls). The telemedicine interventions varied from computerized training programmes with phone calls to videoconferencing programmes, virtual reality classrooms or games. The most applicable method consisted of computerized training programmes with phone calls. Pooling results of all studies with available data on each subscale showed a significant effect of telemedicine on inattention/cognitive function (standardized mean difference (SMD) = 0.26, 95% CI: 0.16, 0.36), hyperactivity/impulsivity (SMD = 0.29, 95% CI: 0.06, 0.52), and oppositional behaviours (SMD = 0.72, 95% CI: 0.24, 1.20) subscales in ADHD. Almost all studies had an overall unclear risk of bias. The source of outcome assessment (parents, teachers or self-report questionnaire) was addressed as a potential confounding factor. In almost all symptom domains, the satisfaction from the treatment was higher in parents than in teachers. Conclusions The clinical effects of telemedicine on the treatment of ADHD showed a small effect size for inattention/cognitive function, hyperactivity/impulsivity and oppositional behaviours.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Amelie Nkodo

Abstract Objectives A systematic review was undertaken of the evidence on the use of Hericium erinaceus (Reishi), Ganoderma lucidum (Lion's Mane), Ophiocordyceps sinensis (Cordyceps) and Cordyceps militaris (Cordyceps), dietary supplementation on cognitive impairment outcomes. Methods Relevant articles were identified in major databases (PubMed, Embase, Web of Science, and SCOPUS). Key search words were Hericium erinaceus, Ganoderma lucidum, Ophiocordyceps sinensis, Lion's mane, Reishi, Cordyceps, cognitive, memory, dementia, Alzheimer's. Included studies were peer-reviewed in-vivo articles published in English before January 2019, with cognitive outcomes. Results Twenty-five (25) of 194 studies met the inclusion criteria: eight (8) studies on lion's mane mushroom, seven (7) studies on reishi mushroom and ten (10) studies on cordyceps mushroom. Three (3) randomized-controlled trials were included in this review. Studies varied by animals used, preparation of supplement, dosage and duration of supplementation, and cognitive outcomes. Twenty-two (22) animal studies found positive results (P < 0.05) on at least one of the doses tested for at least one cognitive impairment outcome. Of the human trials, two (2) studies found positive results (P < 0.05) on at least one of the cognitive assessments. Conclusions Despite heterogeneous study design, the results of this review suggest that dietary supplementation with lion's mane, reishi and cordyceps mushrooms may have a beneficial effect on cognitive impairment. Further clinical research studies are needed to demonstrate the potential medicinal benefits of dietary mushroom supplementation in humans with cognitive impairments. Funding Sources No external funding.


2000 ◽  
Vol 23 (6) ◽  
pp. 401-404 ◽  
Author(s):  
B. RANHEIM ◽  
J. M. ARNEMO ◽  
S. STUEN ◽  
T. E. HORSBERG
Keyword(s):  

1951 ◽  
Vol 19 (4) ◽  
pp. 698-721 ◽  
Author(s):  
James A. Halsted ◽  
William S. Adams ◽  
Sol Sloan ◽  
Robert L. Walters ◽  
Samuel H. Bassett

Sign in / Sign up

Export Citation Format

Share Document